• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Rodgers Cathy Mcmorris

    7/31/25 10:36:14 AM ET
    $MDCX
    Get the next $MDCX alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Rodgers Cathy McMorris

    (Last) (First) (Middle)
    300 CONSHOHOCKEN STATE ROAD
    SUITE 200

    (Street)
    W. CONSHOHOCKEN PA 19428

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    07/22/2025
    3. Issuer Name and Ticker or Trading Symbol
    Medicus Pharma Ltd. [ MDCX ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (right to buy) (1) 07/22/2030 Common Shares 25,000 $3.08 D
    Explanation of Responses:
    1. The option was granted on July 22, 2025. The option is scheduled to vest quarterly in four equal installments over one year.
    Remarks:
    Exhibit List - Exhibit 24.1 - Power of Attorney
    /s/ Raza Bokhari, as Attorney-in-Fact, for Cathy McMorris Rodgers 07/31/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $MDCX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MDCX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MDCX
    SEC Filings

    View All

    SEC Form S-1 filed by Medicus Pharma Ltd.

    S-1 - Medicus Pharma Ltd. (0001997296) (Filer)

    11/19/25 5:00:34 PM ET
    $MDCX

    SEC Form EFFECT filed by Medicus Pharma Ltd.

    EFFECT - Medicus Pharma Ltd. (0001997296) (Filer)

    11/17/25 12:15:23 AM ET
    $MDCX

    SEC Form EFFECT filed by Medicus Pharma Ltd.

    EFFECT - Medicus Pharma Ltd. (0001997296) (Filer)

    11/17/25 12:15:24 AM ET
    $MDCX

    $MDCX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Medicus Pharma Ltd. Explore Novel Treatment Innovations that may Revolutionize Treatments for Prostate and Skin Cancers

    PHILADELPHIA, Nov. 24, 2025 (GLOBE NEWSWIRE) -- November is Men's Health Awareness Month, a time to spotlight the latest medical breakthroughs that may transform how we detect and treat cancer– especially prostate and skin cancer, which are among the most common cancers affecting men.  In advanced prostate cancer, lifelong treatment modalities are making a difference, yet challenges remain for patients with a high cardiovascular risk profile linked to hormone deprivation therapies. "While hormone deprivation therapy has long been the standard for advanced prostate cancer, most of the drugs in this category can raise cardiovascular risks," explained Dr. Raza Bokhari, Executive Chairman &

    11/24/25 8:00:00 AM ET
    $MDCX

    Medicus Pharma Ltd. Announces Filing of FDA Commissioner's National Priority Voucher Application (CNPV) for SKNJCT-003 to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

    PHILADELPHIA, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce that it has submitted an FDA Commissioner's national priority voucher (CNPV) application on behalf of Skinject (SKNJCT-003) evaluating Doxorubicin Microneedle Array (D-MNA) to non-invasively treat basal cell carcinoma (BCC) of the skin. The submission includes a complete Statement of Interest outlining SkinJect's alignment with FDA national priorities in cancer care access, affordability, and rare-disease needs.  

    11/17/25 7:30:00 AM ET
    $MDCX

    Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for SKINJECT™ in Patients with Gorlin Syndrome

    PHILADELPHIA, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce a strategic collaboration with the Gorlin Syndrome Alliance (GSA) to advance compassionate access to SKINJECT™, the Company's investigational doxorubicin containing microneedle arrays (D-MNA) for patients suffering from Gorlin Syndrome, also known as nevoid basal cell carcinoma syndrome. Under the collaboration, Medicus and the GSA will jointly pursue the Expanded Access IND Program with the Food and Drug Adm

    10/29/25 7:30:00 AM ET
    $MDCX

    $MDCX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Mahaffy Patrick J claimed ownership of 35,435 shares (SEC Form 3)

    3 - Medicus Pharma Ltd. (0001997296) (Issuer)

    9/8/25 4:36:44 PM ET
    $MDCX

    Amendment: New insider Smith Andrew Alasdair claimed ownership of 164 shares (SEC Form 3)

    3/A - Medicus Pharma Ltd. (0001997296) (Issuer)

    8/6/25 4:36:34 PM ET
    $MDCX

    SEC Form 3 filed by new insider Rodgers Cathy Mcmorris

    3 - Medicus Pharma Ltd. (0001997296) (Issuer)

    7/31/25 10:36:14 AM ET
    $MDCX

    $MDCX
    Leadership Updates

    Live Leadership Updates

    View All

    Medicus Pharma Ltd. Appoints Faisal Mehmud, MD, MRCP as Chief Medical Officer

    TORONTO and PHILADELPHIA, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd (NASDAQ:MDCX, TSXV:MDCX) (the "Company") is pleased to announce the appointment of Faisal Mehmud, MD as Chief Medical Officer. "We are thrilled to welcome Dr. Mehmud to our leadership team," stated Dr. Raza Bokhari, Exec. Chairman & CEO. "Faisal has a proven track record in integrating cutting-edge science with practical, evidence-based medical strategies to develop partnerships and launch high impact therapies. We aim to capitalize on his experience and expertise to expand our drug development pipeline and foster collaboration with strategic partners to bring to market our novel non-invasive patented dissolvab

    11/18/24 7:30:00 AM ET
    $GSK
    $MDCX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MDCX
    Financials

    Live finance-specific insights

    View All

    Medicus Pharma Ltd. Explore Novel Treatment Innovations that may Revolutionize Treatments for Prostate and Skin Cancers

    PHILADELPHIA, Nov. 24, 2025 (GLOBE NEWSWIRE) -- November is Men's Health Awareness Month, a time to spotlight the latest medical breakthroughs that may transform how we detect and treat cancer– especially prostate and skin cancer, which are among the most common cancers affecting men.  In advanced prostate cancer, lifelong treatment modalities are making a difference, yet challenges remain for patients with a high cardiovascular risk profile linked to hormone deprivation therapies. "While hormone deprivation therapy has long been the standard for advanced prostate cancer, most of the drugs in this category can raise cardiovascular risks," explained Dr. Raza Bokhari, Executive Chairman &

    11/24/25 8:00:00 AM ET
    $MDCX

    Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for SKINJECT™ in Patients with Gorlin Syndrome

    PHILADELPHIA, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce a strategic collaboration with the Gorlin Syndrome Alliance (GSA) to advance compassionate access to SKINJECT™, the Company's investigational doxorubicin containing microneedle arrays (D-MNA) for patients suffering from Gorlin Syndrome, also known as nevoid basal cell carcinoma syndrome. Under the collaboration, Medicus and the GSA will jointly pursue the Expanded Access IND Program with the Food and Drug Adm

    10/29/25 7:30:00 AM ET
    $MDCX